---
canonical_name: Sh-Polypeptide-7
alternate_names: rh-Polypeptide-7, Synthetic Human IGF-1, Recombinant Human Insulin-like Growth Factor 1, IGF-1, IGF-I, Mechano Growth Factor (related splice variant)
canonical_topic: Sh-Polypeptide-7 for Hair Regrowth
short_topic_lc: sh_polypeptide_7_hair
creation_date: 2026-0629-1353
creator_ai_fullname: Opus 4.8
---
# Sh-Polypeptide-7 for Hair Regrowth
Evidence Review created on 06/29/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8
**Also known as:** rh-Polypeptide-7, Synthetic Human IGF-1, Recombinant Human Insulin-like Growth Factor 1, IGF-1, IGF-I, Mechano Growth Factor (related splice variant)
## Motivation
Sh-Polypeptide-7 is the cosmetic-industry label (INCI name) for a lab-made copy of insulin-like growth factor 1 (IGF-1), a signaling protein the body normally produces. In the hair follicle, this protein is made by the small cluster of cells at the follicle base that act as its control center, and it helps push follicles into and keep them in their active growing phase. Because scalp follicles affected by pattern hair loss appear to make less of this protein, applying a synthetic version directly to the scalp has become a popular idea in peptide-based hair serums and in-clinic treatments.
Interest grew from a simple observation: balding follicles secrete noticeably less of this growth factor than neighboring healthy ones, and the same protein partly explains why the standard drug finasteride works. This made it an attractive target for products promising to "feed" struggling follicles without hormones.
This review examines what is actually known about applying synthetic IGF-1 to the scalp for hair regrowth — the biological rationale, the human and laboratory evidence, the considerable gap between mechanism and proven topical results, the safety questions that surround growth factors, and how it compares with established options.
**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
## Recommended Reading
This section lists high-quality, high-level overviews of IGF-1 and hair biology from trusted experts and primary literature, selected to give context beyond the marketing claims.
* [The Science of Healthy Hair, Hair Loss and How to Regrow Hair](https://www.hubermanlab.com/episode/the-science-of-healthy-hair-hair-loss-and-how-to-regrow-hair) - Andrew Huberman
A comprehensive lecture on the biology of hair growth and the mechanical and chemical approaches to slowing loss, including the role of growth factors, blood flow, and follicle stem cells, providing the physiological backdrop against which growth-factor products are positioned.
* [AMA #63: A Guide for Hair Loss — Causes, Treatments, Transplants, and Sex-Specific Considerations](https://peterattiamd.com/ama63/) - Peter Attia
A practitioner-oriented walkthrough of the evidence tiers for hair-loss interventions, useful for situating unproven growth-factor serums relative to first-line options such as minoxidil and finasteride.
* [How Much Protein Should You Eat? Muscle Growth vs. IGF-1 Longevity Concerns](https://www.foundmyfitness.com/episodes/how-much-protein-should-you-eat-muscle-growth-vs-igf-1-longevity-concerns-rhonda-patrick) - Rhonda Patrick
A discussion of IGF-1 signaling biology and its double-edged role in growth and aging, which clarifies why raising this growth factor is not automatically benign.
* [Insulin-like Growth Factor 1 (IGF-1) in Hair Regeneration: Mechanistic Pathways and Therapeutic Potential](https://pubmed.ncbi.nlm.nih.gov/41020895/) - Hsieh et al., 2025
A current narrative review mapping how IGF-1 drives the follicle growth phase through the PI3K/Akt and MAPK/ERK pathways and summarizing the early-stage state of topical delivery, including its limitations.
* [Insulin-like Growth Factor-1: Roles in Androgenetic Alopecia](https://pubmed.ncbi.nlm.nih.gov/24499417/) - Panchaprateep & Asawanonda, 2014
The primary research letter showing that dermal papilla cells from balding scalp secrete significantly less IGF-1 than non-balding cells, the foundational human finding that motivates the entire therapeutic concept.
*Note: No dedicated content discussing IGF-1, growth factors, or Sh-Polypeptide-7 for hair could be found from two of the prioritized experts — Chris Kresser and Life Extension Magazine — so neither is represented above; the five items shown were selected for direct relevance and depth, with no more than one per source.*
## Grokipedia
No Grokipedia article exists for Sh-Polypeptide-7 (or for synthetic human IGF-1 as a hair-regrowth intervention) as of June 2026.
## Examine
No Examine article exists for Sh-Polypeptide-7. Examine covers orally ingested dietary supplements and does not typically cover topical cosmetic peptide ingredients identified by their INCI (cosmetic-labeling) name.
## ConsumerLab
No ConsumerLab article exists for Sh-Polypeptide-7. ConsumerLab tests ingestible dietary supplements and does not typically cover topical cosmetic peptide ingredients identified by their INCI name.
## Systematic Reviews
This section lists systematic reviews and meta-analyses relevant to growth-factor and regenerative therapies for hair loss, the closest evidence category to topical synthetic IGF-1.
* [The Efficacy of Growth Factor Injection in Androgenic Alopecia: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/42126441/) - Alali et al., 2026
Pooling twelve studies (745 patients) of injected growth-factor concentrates and platelet-rich plasma for pattern hair loss, it reports density gains over 12 months but flags high risk of bias, extreme heterogeneity, and non-standardized protocols, judging the evidence hypothesis-generating rather than confirmatory.
* [Regenerative Medicine in the Treatment of Specific Dermatologic Disorders: A Systematic Review of Randomized Controlled Clinical Trials](https://pubmed.ncbi.nlm.nih.gov/38886861/) - Jafarzadeh et al., 2024
A review of 64 randomized trials (2888 patients) in which androgenetic alopecia was the most-studied condition; growth-factor and platelet-based regenerative methods showed improvement up to 68.4%, but the interventions are injectable concentrates, not standardized single-molecule topical IGF-1.
* [Effectiveness of Minimally Invasive Injectable Modalities in the Management of Androgenetic Alopecia Among Adults — A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/39176982/) - Kumar et al., 2024
A systematic comparison of injectable modalities including platelet-rich plasma and growth-factor preparations, useful for gauging how isolated growth-factor delivery performs against the broader injectable field.
No systematic review or meta-analysis has yet evaluated Sh-Polypeptide-7 (synthetic human IGF-1) as a standalone topical hair-regrowth ingredient specifically; the reviews above address the adjacent and better-studied category of injected growth-factor and regenerative therapies.
## Mechanism of Action
Sh-Polypeptide-7 is a synthetic, recombinant copy of insulin-like growth factor 1 (IGF-1), a 70-amino-acid protein. Its relevance to hair rests on several converging actions:
* **Anagen induction and maintenance:** In the hair follicle, IGF-1 is produced mainly by dermal papilla cells (the signaling hub at the follicle base) and acts on follicle keratinocytes to drive entry into and prolongation of the anagen (active growth) phase, delaying the regression (catagen) and resting (telogen) phases.
* **Pro-proliferative and anti-apoptotic signaling:** IGF-1 binds the IGF-1 receptor and activates the PI3K/Akt pathway (a master cell-survival and growth cascade — phosphoinositide 3-kinase / protein kinase B) and the MAPK/ERK pathway (mitogen-activated protein kinase / extracellular signal-regulated kinase, which drives cell division). This stimulates keratinocyte proliferation and suppresses programmed cell death in the follicle.
* **Vascular and trophic support:** IGF-1 upregulates VEGF (vascular endothelial growth factor, a signal that builds blood vessels), improving microcirculation and nutrient delivery to the follicle, and its effects are amplified by co-signaling growth factors such as KGF/FGF-7 (keratinocyte growth factor) and PDGF (platelet-derived growth factor).
* **Link to androgen biology:** IGF-1 is partly androgen-regulated. Research indicates that the androgen receptor drives a small regulatory RNA (miR-221) that suppresses IGF-1, and that finasteride's benefit correlates with restored follicular IGF-1 expression — placing IGF-1 downstream of the hormonal cause of pattern hair loss rather than acting on it directly.
Competing mechanistic interpretations exist. The pro-hair view holds that restoring depleted local IGF-1 reactivates dormant follicles. A counter-view, supported by aging biology, holds that chronically elevated skin IGF-1 can instead push hair follicle stem cells into senescence (a dysfunctional, non-dividing state), accelerating follicle aging — so the relationship between IGF-1 level and hair health may be non-linear, with both deficiency and excess being harmful.
**Pharmacological properties (as a topical protein):** Native IGF-1 circulates bound to binding proteins with a complexed half-life of several hours, but free IGF-1 is cleared within minutes. As a large protein, IGF-1 penetrates intact skin poorly, so topical delivery depends heavily on the formulation (liposomal gels, microneedling, or exosome carriers). It is not metabolized by cytochrome P450 enzymes; like other peptides it is broken down by proteases into amino acids. Selectivity is for the IGF-1 receptor, with weaker cross-reactivity at the insulin receptor.
## Historical Context & Evolution
* **Original intended use:** IGF-1 was first characterized as a mediator of growth hormone's effects on body-wide tissue growth; recombinant IGF-1 (mecasermin) was developed as a prescription drug for severe primary IGF-1 deficiency and short stature in children, not for hair.
* **Path to hair optimization:** Dermatology research from the 1990s onward established that IGF-1 is a key positive regulator of the hair cycle. The pivotal human finding came in 2014, when Panchaprateep and Asawanonda showed that dermal papilla cells from balding scalp secrete significantly less IGF-1 than non-balding cells — recasting pattern hair loss partly as a local growth-factor deficiency and motivating the idea of topical replacement.
* **What the historical research actually found:** Animal studies showed exogenous IGF-1 increases follicle number and prolongs anagen; human organ-culture work showed IGF-1 increases the rate at which hair fibers elongate. These are consistent positive signals at the tissue level, distinct from proof that a topically applied serum reaches the follicle and regrows hair in people.
* **Translation into cosmetics:** Because IGF-1 is a prescription biologic when injected systemically, its use in over-the-counter products proceeds under the cosmetic INCI name "Sh-Polypeptide-7" ("sh" = synthetic human), formulated into scalp sprays and serums marketed for hair density rather than as approved drugs.
* **Evolving and unsettled opinion:** The early framing of "more IGF-1 = more hair" has been complicated by 2025 aging-biology findings that excess epidermal IGF-1 can drive follicle stem-cell senescence and hair loss. Rather than overturning the deficiency hypothesis, this suggests the field is moving toward a dose- and context-dependent understanding that is not yet resolved.
## Expected Benefits
A dedicated search of clinical, mechanistic, and expert sources was performed for the complete benefit profile of synthetic/topical IGF-1 in hair. The evidence is dominated by laboratory and injectable-concentrate data; direct evidence for the topical cosmetic ingredient is minimal, which is reflected in the conservative grades below.
### High 🟩 🟩 🟩
(No benefits of topical Sh-Polypeptide-7 meet the High evidence bar, which requires consistent randomized controlled trials or meta-analyses of the specific topical intervention. None exist.)
### Medium 🟩 🟩
(No benefits meet the Medium bar for the specific topical intervention.)
### Low 🟩
#### Promotion and prolongation of the hair growth phase ⚠️ Conflicted
IGF-1 is one of the most consistently identified positive regulators of the anagen (growth) phase. In animal models, exogenous IGF-1 increases follicle number and extends anagen, and in human follicle organ culture it increases the hair-fiber elongation rate. The proposed mechanism is PI3K/Akt and MAPK/ERK activation in follicle keratinocytes. The evidence is graded Low because it derives almost entirely from preclinical and ex-vivo models rather than controlled trials of the topical ingredient in people; it is flagged conflicted because aging-biology data indicate excess IGF-1 can instead drive follicle stem-cell senescence and hair loss.
**Magnitude:** In human follicle organ culture, IGF-1 increased fiber elongation to roughly 0.10 mm/day versus about 0.08 mm/day in controls (≈25% relative increase); no validated regrowth magnitude exists for the topical product in humans.
#### Adjunctive density gains within growth-factor / regenerative protocols
When growth factors are delivered as injected concentrates (platelet-rich plasma, growth-factor concentrate) for pattern hair loss, pooled analyses report measurable density and thickness gains, and IGF-1 is one component of these mixtures. This provides indirect support that locally delivered growth-factor signaling can influence hair density. The grade is Low and the relevance is indirect: these are multi-factor injectable preparations, not standardized topical Sh-Polypeptide-7, and the underlying trials carry high risk of bias and extreme heterogeneity.
**Magnitude:** Across pooled injectable growth-factor studies, hair-density increases of roughly 20–57 hairs/cm² over 12 months have been reported, but these are not attributable to topical Sh-Polypeptide-7 specifically.
### Speculative 🟨
#### Replacement of follicular IGF-1 deficiency in pattern hair loss
Because balding-scalp dermal papilla cells secrete less IGF-1 than healthy follicles, topically restoring local IGF-1 is hypothesized to reactivate underperforming follicles. The basis is mechanistic and correlational (the 2014 deficiency finding plus the finasteride–IGF-1 correlation); no controlled human study demonstrates that a topical serum restores follicular IGF-1 or regrows hair, and skin penetration of an intact protein is a major unresolved barrier.
#### Synergy with co-applied growth factors and microneedling
Formulations pair Sh-Polypeptide-7 with other growth factors (VEGF, KGF, PDGF) and with microneedling to enhance delivery, and the combined signaling could plausibly outperform IGF-1 alone. This is supported only by mechanistic reasoning and the broader regenerative-injectable literature, with no isolated evidence for the specific topical combination.
## Benefit-Modifying Factors
* **Androgen status and hormonal cause:** Because pattern hair loss is androgen-driven and IGF-1 sits downstream of androgen receptor signaling, any benefit may be limited if the upstream hormonal driver (dihydrotestosterone activity) is not also addressed; IGF-1 replacement does not block the cause.
* **Genetic polymorphisms (androgen-receptor sensitivity):** The strongest genetic predictor of pattern hair loss is variation in the *AR* gene (androgen receptor, the protein that binds dihydrotestosterone); shorter CAG-repeat lengths increase receptor sensitivity and tend to drive more aggressive miniaturization. Because IGF-1 acts downstream of this receptor, individuals with high-sensitivity AR variants may see less benefit from growth-factor signaling unless the upstream androgen driver is also lowered.
* **Baseline follicular IGF-1 / miniaturization stage:** The deficiency rationale predicts greater potential benefit in follicles that are underperforming but not yet fully miniaturized; long-dormant or scarred follicles are unlikely to respond to growth-factor signaling regardless of dose.
* **Delivery and formulation:** Benefit is gated by whether the intact protein actually reaches the dermal papilla. Liposomal encapsulation, exosome carriers, or microneedling substantially change the realistic benefit relative to a simple topical solution.
* **Sex-based differences:** The foundational deficiency data derive from male balding scalp. Female pattern hair loss has a different hormonal context and a less-defined relationship to follicular IGF-1, so benefit cannot be assumed equivalent across sexes.
* **Age-related considerations:** In older individuals, skin IGF-1 tends to rise with age and has been linked to follicle stem-cell senescence; adding exogenous IGF-1 in this setting may yield diminishing or even counterproductive effects, making age a meaningful modifier at the older end of the target range.
## Potential Risks & Side Effects
A dedicated search of drug-reference, pharmacovigilance, and primary literature was performed for the side-effect profile of IGF-1 and topical growth-factor products. Most documented systemic risks derive from injected/systemic IGF-1; for the topical cosmetic ingredient, the principal concern is theoretical proliferative risk plus formulation-related local effects.
### High 🟥 🟥 🟥
(No risks of topical Sh-Polypeptide-7 meet the High evidence bar from controlled study of the topical ingredient.)
### Medium 🟥 🟥
#### Theoretical proliferative and oncological concern from a growth factor
IGF-1 is a potent mitogen and anti-apoptotic signal, and elevated systemic IGF-1 is epidemiologically associated with increased risk of several cancers. Applying a proliferation-promoting growth factor to skin raises a theoretical concern about stimulating unwanted cell growth, particularly over precancerous lesions or in individuals with a personal cancer history. The evidence is graded Medium because the carcinogenic association of IGF-1 systemically is well established, even though topical penetration and local risk are unproven; this is the most-cited safety argument in the cosmetic-safety literature on growth-factor products.
**Magnitude:** Not quantified in available studies for topical scalp use; systemic epidemiology shows higher-tertile IGF-1 associates with modestly increased risk for certain cancers, but topical exposure magnitude is unknown.
### Low 🟥
#### Local scalp irritation, redness, and folliculitis
As with most scalp serums, the vehicle (preservatives, solubilizers, alcohols) and any accompanying microneedling can cause irritation, redness, itching, or superficial folliculitis. The mechanism is direct local irritation or barrier disruption rather than the peptide itself. The grade is Low because these effects are common to topical scalp products generally and are typically mild and reversible.
**Magnitude:** Not quantified in available studies.
#### Paradoxical follicle aging from IGF-1 excess
Aging-biology research shows that ectopic, elevated epidermal IGF-1 can push hair follicle stem cells into senescence, accelerating graying and hair loss in animal models. This raises the possibility that overdosing local IGF-1 could be counterproductive for hair. The grade is Low for the topical product because the finding comes from transgenic-overexpression and mouse models rather than human topical use.
**Magnitude:** Not quantified in available studies.
### Speculative 🟨
#### Endocrine effects from systemic absorption
If a topical IGF-1 product were absorbed in meaningful quantity, systemic IGF-1 elevation could theoretically affect blood sugar (hypoglycemia) and other endocrine endpoints, as seen with injected IGF-1 therapeutics. This is speculative for cosmetic topicals because intact-protein skin penetration is generally very low and no systemic levels have been demonstrated from such products.
#### Unknown effects of contaminants or mislabeled potency
Because these are unregulated cosmetic products rather than approved biologics, the actual IGF-1 content, activity, and purity may differ from label claims, introducing unquantified risk from degradation products or contaminants. The basis is the general regulatory gap for cosmetic growth-factor products, not specific incident reports.
## Risk-Modifying Factors
* **Personal or family cancer history:** Given IGF-1's mitogenic profile, a personal history of skin or hormone-sensitive cancers, or active precancerous scalp lesions, amplifies the theoretical proliferative concern and is the most relevant risk modifier.
* **Genetic polymorphisms (IGF-1 axis and cancer susceptibility):** Common variants in the *IGF1* gene and its receptor (*IGF1R*) influence circulating IGF-1 levels and signaling strength, and certain alleles are associated with higher baseline IGF-1 or greater cancer susceptibility; individuals carrying high-IGF-1 or proliferation-prone variants are theoretically the least suitable candidates for adding an external growth-factor signal, particularly where systemic absorption is plausible.
* **Baseline IGF-1 and metabolic status:** Individuals with already-high systemic IGF-1 (e.g., acromegaly) or insulin-resistant states represent a context where added IGF-1 signaling is least desirable; baseline metabolic biomarkers are relevant where systemic absorption is plausible.
* **Sex-based differences:** Hormonal milieu differs by sex; women who are pregnant or breastfeeding are routinely advised to avoid growth-factor cosmetics because effects on the fetus or infant are untested.
* **Pre-existing scalp conditions:** Active dermatitis, psoriasis, infection, or a disrupted scalp barrier increases both irritation risk and the likelihood of greater-than-expected absorption.
* **Age-related considerations:** Older adults already exhibit rising skin IGF-1 linked to follicle senescence; adding exogenous growth factor in this group may shift the balance toward the paradoxical-aging risk noted above.
## Key Interactions & Contraindications
* **Topical minoxidil (over-the-counter vasodilator):** Commonly stacked in hair routines. No documented harmful interaction; both increase follicular activity and the combination is additive rather than antagonistic. Severity: caution only. Mitigation: introduce one product at a time to attribute any irritation.
* **5-alpha-reductase inhibitors (finasteride, dutasteride — prescription DHT blockers):** Mechanistically complementary, since these drugs restore follicular IGF-1 by lowering dihydrotestosterone. No adverse interaction is described. Severity: monitor; consequence: potential additive benefit, not harm.
* **Other topical growth factors and peptides (VEGF, KGF/FGF-7, PDGF, copper peptides):** Frequently co-formulated; additive proliferative signaling. Severity: caution. Consequence: amplified local growth-factor load, which is also the basis of the theoretical proliferative concern.
* **Microneedling and other barrier-disrupting procedures:** These deliberately increase penetration, raising both efficacy and systemic-absorption potential. Severity: caution. Mitigation: separate aggressive procedures from application and avoid on broken or infected skin.
* **Retinoids and exfoliating acids on the scalp:** May increase irritation and barrier disruption when layered with a growth-factor serum. Severity: caution; mitigation: time-separate applications.
* **Populations who should avoid this intervention:**
- Anyone with a current or recent malignancy, especially skin or hormone-sensitive cancers, or active precancerous scalp lesions (theoretical proliferative risk).
- Pregnant or breastfeeding individuals (untested; growth-factor cosmetics are routinely contraindicated here).
- People with acromegaly or other states of pathologically elevated IGF-1.
- Individuals with active scalp infection, open wounds, or uncontrolled inflammatory scalp disease.
## Risk Mitigation Strategies
* **Patch test before scalp-wide use:** Apply a small amount to a limited area for several days to screen for irritation or allergic reaction before broader application, mitigating local irritation, redness, and folliculitis.
* **Avoid use over lesions and in cancer-risk contexts:** Do not apply over moles, precancerous keratoses, or recent surgical sites, and avoid entirely with a personal history of skin or hormone-sensitive cancer, directly addressing the theoretical proliferative/oncological concern.
* **Keep the lowest effective frequency and avoid layering multiple growth factors:** Using a single growth-factor product at the manufacturer's recommended (typically once- or twice-daily) frequency, rather than stacking several, limits total proliferative signaling and the paradoxical follicle-senescence risk.
* **Separate from barrier-disrupting steps:** Apply away from same-session microneedling, retinoids, or acids, and never on broken or infected skin, to limit excess absorption and irritation.
* **Prefer products with transparent sourcing and third-party verification:** Choosing serums from manufacturers that disclose peptide source and provide independent purity/potency testing mitigates the unregulated-cosmetic risk of mislabeled potency or contaminants.
* **Discontinue on adverse signs:** Stopping at the first sign of persistent irritation, new or changing scalp lesions, or unexpected systemic symptoms limits harm from both local and (theoretical) systemic effects.
## Therapeutic Protocol
There is no validated, evidence-based clinical protocol for topical Sh-Polypeptide-7; the points below describe how leading hair-restoration practitioners and product manufacturers typically position growth-factor serums, which remain adjunctive rather than first-line.
* **Standard practitioner positioning:** Hair-restoration physicians (e.g., the approach discussed by Alan Bauman in Peter Attia's hair-loss content) generally treat growth-factor topicals as an add-on to evidence-based first-line therapy (minoxidil, finasteride/dutasteride), not as a replacement, given the weak standalone evidence.
* **Competing approaches without a default:** Two broad strategies coexist — topical application (serums/sprays containing Sh-Polypeptide-7, often with other growth factors) and in-office injectable delivery (platelet-rich plasma or growth-factor concentrate, sometimes with microneedling). The injectable route has more (though still low-quality) clinical data; the topical route is more convenient but faces the protein-penetration barrier. Neither is established as superior for the isolated ingredient.
* **Delivery enhancement:** Because intact IGF-1 penetrates skin poorly, protocols frequently combine the serum with microneedling or use liposomal/exosome carriers to improve follicular delivery; this is the single most important practical variable.
* **Best time of day:** No circadian advantage is established; products are typically applied once or twice daily to a clean, dry scalp consistent with general topical-serum practice.
* **Half-life consideration:** Free IGF-1 is cleared from circulation within minutes and as a protein is rapidly degraded by skin proteases, which is the rationale for repeated daily application and for delivery systems that protect and slowly release the peptide.
* **Single vs. split dosing:** Given rapid local degradation, manufacturers favor twice-daily split application over a single daily dose to sustain follicular exposure.
* **Genetic considerations:** Androgen-receptor sensitivity (the principal genetic driver of pattern hair loss) sits upstream of IGF-1; individuals with strong androgenic miniaturization may need concurrent DHT-lowering therapy for any growth-factor approach to matter.
* **Sex-based differences:** Protocols derived from male-pattern data may not transfer to female pattern hair loss, where the hormonal context and the IGF-1 relationship are less defined; dosing in women is empirical.
* **Age-related considerations:** In older users with already-elevated skin IGF-1, a conservative frequency is reasonable given the senescence concern.
* **Baseline biomarkers:** No specific biomarker gates topical use, but documenting baseline scalp density (global photography, phototrichogram) is the practical way to judge response.
* **Pre-existing conditions:** Active scalp inflammation or infection should be treated before starting, since it alters both response and absorption.
## Discontinuation & Cycling
* **Lifelong vs. short-term:** Like other hair-density interventions, any benefit is presumed to depend on continued use; pattern hair loss is progressive, so stopping is expected to allow gradual return toward the untreated trajectory. No data define a durable post-treatment effect.
* **Withdrawal effects:** No specific withdrawal syndrome is documented for topical IGF-1; the main consequence of stopping is loss of any maintained density over subsequent months, paralleling discontinuation of minoxidil.
* **Tapering:** No tapering protocol is established or necessary; abrupt discontinuation has no known rebound effect beyond loss of effect.
* **Cycling:** No evidence supports cycling for efficacy. A theoretical argument for periodic breaks exists only in the context of limiting cumulative growth-factor exposure given the proliferative and senescence concerns, but this is not data-driven.
* **Practical framing:** Because efficacy itself is unproven, discontinuation decisions are typically driven by lack of visible benefit, cost, or emergence of irritation rather than by a defined schedule.
## Sourcing and Quality
* **Recombinant source and purity:** Sh-Polypeptide-7 is produced by recombinant DNA technology ("sh" denotes synthetic human). Because it is sold as a cosmetic ingredient rather than an approved biologic, manufacturing standards vary; look for disclosure of expression system, purity, and peptide concentration.
* **Third-party testing and stability:** Prefer products that provide independent verification of identity, potency, and absence of contaminants, and that address cold-chain or stability handling, since IGF-1 is a labile protein that degrades with heat and time.
* **Formulation and delivery system:** What to look for is an explicit delivery strategy (liposomal encapsulation, exosome carriers, or paired microneedling), because an unencapsulated protein in a simple solution is unlikely to penetrate to the follicle.
* **Reputable product categories:** Clinic-dispensed growth-factor systems (e.g., KeraFactor-type in-office serums) and established peptide hair sprays (e.g., KERAVIVE-type peptide sprays, Saturday Skin scalp peptide treatments) list Sh-Polypeptide-7 among their ingredients; clinic-channel products generally carry more formulation accountability than anonymous marketplace serums.
* **Realistic expectation of labeled content:** Because potency is unregulated, treat label claims cautiously; the actual active IGF-1 content and bioactivity may differ substantially from what is stated.
## Practical Considerations
* **Time to effect:** Hair interventions generally require 3–6 months of consistent use before any density change is visible, reflecting the hair cycle; there is no validated timeline for topical Sh-Polypeptide-7 specifically.
* **Common pitfalls:** The most common mistakes are expecting a standalone growth-factor serum to match drug therapy, neglecting the delivery problem (applying an intact protein with no penetration strategy), and stacking multiple growth-factor products without regard to cumulative exposure.
* **Regulatory status:** In most markets, Sh-Polypeptide-7 is used in cosmetic products that make appearance claims, not approved drug claims; topical/injected IGF-1 for hair is off-label and unapproved as a therapy. Systemic recombinant IGF-1 (mecasermin) is a regulated prescription drug for unrelated indications.
* **Cost and accessibility:** Growth-factor serums and especially in-office growth-factor or platelet treatments can be substantially more expensive than first-line topical drugs, with uncertain incremental benefit; this cost-to-evidence mismatch is the main accessibility consideration.
## Interaction with Foundational Habits
* **Sleep:** The interaction is indirect. Growth hormone, the upstream driver of systemic IGF-1, is secreted predominantly during deep sleep, so chronic sleep deprivation lowers endogenous IGF-1; while this concerns systemic rather than scalp IGF-1, adequate sleep supports the body's own growth-factor milieu. No direct effect of the topical product on sleep is known.
* **Nutrition:** The interaction is indirect and bidirectional. Protein and overall energy intake regulate endogenous IGF-1 (severe restriction lowers it), and insulin/IGF-1 signaling is linked to dietary carbohydrate and protein load. Practically, very low-protein or severely calorie-restricted diets reduce the body's own IGF-1 environment; no specific food needs to be paired with or avoided around topical application.
* **Exercise:** The interaction is indirect and generally potentiating. Resistance and high-intensity exercise transiently raise systemic and local IGF-1 and improve scalp microcirculation, which is mechanistically aligned with follicular support. There is no need to time topical application around workouts, though applying to a clean scalp after sweating is sensible.
* **Stress management:** The interaction is indirect. Chronic stress elevates cortisol, which can shift follicles toward the resting phase and is associated with stress-related shedding; managing stress supports the hair cycle generally and counteracts a catabolic hormonal state that opposes growth-factor signaling. No direct effect on cortisol from the topical product is established.
## Monitoring Protocol & Defining Success
Because topical Sh-Polypeptide-7 is an unapproved cosmetic intervention with no validated biomarker, monitoring centers on objective hair measures plus screening labs only where systemic IGF-1 exposure or metabolic risk is a concern. Baseline assessment should be performed before starting, with standardized scalp photography documented at the outset.
Ongoing monitoring follows the hair cycle: reassess at roughly 3 months, 6 months, then every 6–12 months, since visible density change requires multiple months. Laboratory monitoring is optional and reserved for individuals where systemic absorption or metabolic status is a consideration.
* Baseline testing is introduced here as a deliberate first step: capture standardized global scalp photographs and, where available, a phototrichogram before any product use, so that later change can be judged objectively rather than by impression.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Hair density (phototrichogram, hairs/cm²) | Stable or increasing vs. baseline | Objective measure of response | Same scalp region, lighting, and device each visit; reassess at 3, 6, then every 6–12 months |
| Fasting serum IGF-1 (ng/mL) | Age- and sex-adjusted mid-normal range | Screens for systemic elevation if absorption is a concern | Optional; relevant mainly with microneedling-enhanced delivery or pre-existing IGF-1 disorders; draw fasting, morning |
| Fasting glucose / HbA1c | Glucose <90 mg/dL; HbA1c <5.4% | IGF-1 signaling overlaps insulin signaling; screens metabolic context | HbA1c (hemoglobin A1c, a measure of average blood sugar over ~3 months); optional baseline; conventional reference (glucose <100, HbA1c <5.7%) is broader than the functional target shown |
| Ferritin | 40–70 ng/mL (functional target for hair) | Low iron stores independently impair hair growth and confound results | Conventional "normal" extends much lower (>15–30 ng/mL); fasting not required; pairs well with a full iron panel |
| TSH (thyroid-stimulating hormone) | 0.5–2.5 mIU/L (functional) | Thyroid dysfunction is a common, treatable cause of hair shedding that confounds results | Conventional upper limit (~4.0–4.5) is higher; best drawn in the morning, paired with free T4 |
* **Qualitative markers to track:**
- Reduced daily shedding (hairs on pillow, in shower, on brush)
- Subjective scalp coverage and styling ease
- Visible regrowth of short, fine "vellus-to-terminal" hairs at the hairline or part
- Absence of scalp irritation, redness, or new/changing lesions
## Emerging Research
* **No registered hair-specific trials of Sh-Polypeptide-7:** A search of ClinicalTrials.gov returned no interventional trials evaluating Sh-Polypeptide-7 (synthetic human IGF-1) as a topical hair-regrowth treatment as of June 2026; registry activity around IGF-1 concerns endocrine, oncologic, and growth-disorder indications rather than hair.
* **IGF-1 mimetic peptides as a strengthening direction:** [Self-assembling peptide inspired by insulin and type 1 insulin-like growth factor for the treatment of androgenetic alopecia](https://pubmed.ncbi.nlm.nih.gov/40822304/) (Hu et al., 2025) reports that a small IGF-1-mimetic self-assembling peptide (Ac-GFFY-IGF) promoted hair regrowth more effectively than minoxidil and native IGF-1 in a preclinical model, with better stability and skin permeability — a line of work that could strengthen the case for IGF-1-pathway targeting while sidestepping the delivery limits of the full protein.
* **Mechanistic consolidation:** The 2025 review by [Hsieh et al.](https://pubmed.ncbi.nlm.nih.gov/41020895/) maps remaining gaps in topical IGF-1 delivery (liposomal gels, exosome carriers) and calls for controlled long-term human studies, directly framing where the topical concept must be tested.
* **Aging-biology counter-evidence:** [Targeting IGF1-Induced Cellular Senescence to Rejuvenate Hair Follicle Aging](https://pubmed.ncbi.nlm.nih.gov/40159808/) (Wang et al., 2025) shows that excess epidermal IGF-1 drives follicle stem-cell senescence and hair loss in mice — research that could weaken the "more IGF-1 is better" rationale and reframe optimal dosing.
* **Androgen-pathway mechanism:** [The AR/miR-221/IGF-1 pathway mediates the pathogenesis of androgenetic alopecia](https://pubmed.ncbi.nlm.nih.gov/37496996/) (Li et al., 2023) clarifies how androgens suppress follicular IGF-1, identifying upstream targets (miR-221) that future therapies might address instead of supplementing IGF-1 directly.
* **Future research areas:** The decisive open questions are whether an intact topical protein can reach the dermal papilla in humans, the dose at which benefit turns to senescence-driven harm, and whether randomized controlled trials of standardized Sh-Polypeptide-7 (versus vehicle and versus minoxidil) show real-world regrowth. Until such trials exist, the intervention's standing remains mechanistic and hypothesis-generating.
## Conclusion
Sh-Polypeptide-7 is a lab-made copy of the natural growth factor IGF-1, sold as a cosmetic ingredient in scalp serums and clinic treatments aimed at thinning hair. Its appeal is well-grounded in biology: this growth factor helps keep hair in its active growth phase, balding follicles make less of it, and it sits along the same hormonal pathway that the standard hair-loss drug finasteride works through. Laboratory and animal studies consistently show that adding IGF-1 can lengthen the growth phase and boost follicle activity.
The gap between this promise and proof, however, is wide. There are no controlled human trials of the topical product itself, the related evidence comes from injected growth-factor mixtures of uneven quality, and a large protein like this struggles to penetrate the scalp at all without special delivery methods. Newer aging research adds an important caution: too much of this growth factor may push follicle stem cells into a worn-out state and worsen hair loss, so more is not reliably better. There are also unresolved safety questions, since growth factors encourage cells to multiply and the products are largely unregulated. Overall, the idea is mechanistically reasonable but the human evidence is thin and uncertain, placing this firmly in the experimental category rather than among established options.
**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**